Cover Image
市場調查報告書

霍亂 : 開發平台分析

Cholera - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 246032
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
霍亂 : 開發平台分析 Cholera - Pipeline Review, H1 2017
出版日期: 2017年02月28日 內容資訊: 英文 42 Pages
簡介

所謂霍亂,是以霍亂菌為病原體的急性感染疾病,人感染時不會疼痛,會發生水分多的腹瀉。感染後,從數小時最遲在5日內出現症狀。症狀通常為輕症,不過也有達到重症的情況。主要的前兆、症狀為心律的劇增,及皮膚的彈性低、血壓低、喉嚨的乾渴、筋痙攣等。未治療的情況也可能引起休克,數小時便死亡。

本報告提供全球各國的霍亂治療用的開發中產品的開發情形相關分析、產品開發、上市的最新趨勢,及各臨床實驗階段的產品一覽、主要企業簡介、主要藥物概要、最新的產業趨勢等資訊,為您概述為以下內容。

目錄

簡介

  • 分析範圍

霍亂概要

治療藥的開發

  • 霍亂的開發中產品:概要
  • 霍亂的開發中產品:比較分析

各企業開發中的霍亂治療藥

大學/研究機關研究中的霍亂治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

霍亂治療藥:開發中的產品一覽(各企業)

霍亂治療藥:研究中的產品一覽(各大學/研究機關)

霍亂開發治療藥的企業

  • Akthelia pharmaceuticals ehf
  • Beijing Minhai Biotechnology Co., Ltd
  • PaxVax

霍亂:治療藥的評估

  • 單劑治療藥的情況
  • 各標靶
  • 各作用機制
  • 各投藥法
  • 各分子類型

藥物簡介

  • AKT-10082
    • 產品概要
    • 功能機制
    • 研究開發(R&D)的發展情形
  • 三價值霍亂疫苗
  • crofelemer的DR(延遲放出)AKT-10082
  • IMSUTMR-1501
  • 霍亂、格巴二氏症候群用肽
  • PXVX-0200

霍亂治療藥:開發中產品的最新趨勢

霍亂治療藥:開發暫停的產品

霍亂治療藥:開發中止的產品

霍亂相關產品的開發里程碑

  • 值得注意的最新趨勢、新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8989IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cholera - Pipeline Review, H1 2017, provides an overview of the Cholera (Infectious Disease) pipeline landscape.

Cholera is an acute infectious disease caused by a bacterium, Vibrio cholera, which results in a painless, watery diarrhea in humans. Symptoms of cholera can begin as soon as a few hours or as long as five days after infection. Often symptoms are mild. But sometimes they are very serious. Signs and symptoms of Cholera include rapid heart rate, loss of skin elasticity, low blood pressure, thirst, muscle cramps. If not treated, this can lead to shock and death in a matter of hours.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cholera - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cholera (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cholera (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cholera and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 5 and 2 molecules, respectively.

Cholera (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cholera (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cholera (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cholera (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cholera (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cholera (Infectious Disease)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cholera (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cholera (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cholera - Overview
  • Cholera - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cholera - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cholera - Companies Involved in Therapeutics Development
    • Akthelia Pharmaceuticals Ltd
    • Beijing Minhai Biotechnology Co Ltd
    • MSD Wellcome Trust Hilleman Laboratories Pvt Ltd
    • Napo Pharmaceuticals Inc
  • Cholera - Drug Profiles
    • AKT-10082 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera (trivalent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera (whole cell) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cholera vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cholvax - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • crofelemer DR - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • gram-negative bacterial infections vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMSUTMR-1501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptides to Disrupt Cell Membrane for Bacterial and Fungal Infections - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cholera - Dormant Projects
  • Cholera - Discontinued Products
  • Cholera - Product Development Milestones
    • Featured News & Press Releases
      • Apr 27, 2016: Hilleman Laboratories Provides Phase I/II Update on Cholera Vaccine
      • Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Cholera, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cholera - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017
  • Cholera - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2017
  • Cholera - Pipeline by MSD Wellcome Trust Hilleman Laboratories Pvt Ltd, H1 2017
  • Cholera - Pipeline by Napo Pharmaceuticals Inc, H1 2017
  • Cholera - Dormant Projects, H1 2017
  • Cholera - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Cholera, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top